Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
OPCH 
Option Care Health Inc (OPCH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: OPCH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -3.57% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.45B USD | Price to earnings Ratio 26.89 | 1Y Target Price 31.56 |
Price to earnings Ratio 26.89 | 1Y Target Price 31.56 | ||
Volume (30-day avg) 1751290 | Beta 1.35 | 52 Weeks Range 21.39 - 34.17 | Updated Date 02/21/2025 |
52 Weeks Range 21.39 - 34.17 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.19 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-20 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 4.37% | Operating Margin (TTM) 6.66% |
Management Effectiveness
Return on Assets (TTM) 5.98% | Return on Equity (TTM) 14.57% |
Valuation
Trailing PE 26.89 | Forward PE 26.25 | Enterprise Value 6185985428 | Price to Sales(TTM) 1.14 |
Enterprise Value 6185985428 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 1.3 | Enterprise Value to EBITDA 15.71 | Shares Outstanding 170180992 | Shares Floating 169092078 |
Shares Outstanding 170180992 | Shares Floating 169092078 | ||
Percent Insiders 0.6 | Percent Institutions 98.18 |
AI Summary
Option Care Health Inc. (Symbol: OPCH) - Comprehensive Overview
Company Profile:
History and Background:
- Founded in 1994 as Claris Healthcare
- Initially focused on home infusion therapy
- 2007: Acquired by BioScrip, becoming BioScrip Infusion Services
- 2015: Renamed to Option Care
- 2017: Completed IPO
- 2020: Acquired Clinical Pharmacy, expanding its product offerings
Core Business Areas:
- Home and Alternate Site Infusion Therapy: Delivers medication directly to patients' homes or other settings
- Specialty Pharmacy Services: Provides specialty medications to patients with chronic or complex conditions
- Nursing Services: Offers skilled nursing care to patients in various settings
Leadership Team and Corporate Structure:
- President and Chief Executive Officer: John Rademacher
- Chief Financial Officer: Heather D. Pistulka
- Executive Vice President and Chief Operating Officer: Douglas O'Neil
- Board of Directors: Comprised of experienced professionals with expertise in healthcare, finance, and business operations
Top Products and Market Share:
- Top product: Home infusion therapy (estimated 70% of revenue)
- Other products: Specialty pharmacy services, nursing services
- Global market share: Difficult to estimate due to the diverse nature of the industry
- US market share: 20-25% of the home infusion therapy market
- Competition: Baxter, Fresenius Kabi, CVS Health, Walgreens Boots Alliance
Total Addressable Market:
- Global home infusion therapy market: Estimated at $35-40 billion in 2023
- US home infusion therapy market: Estimated at $15-20 billion in 2023
Financial Performance:
- Revenue: Increased steadily in recent years, with $3.3 billion in 2022
- Net income: Fluctuated in recent years, with $153 million in 2022
- Profit margins: Declined slightly in 2022, with an operating margin of 4.4%
- Earnings per share (EPS): $3.71 in 2022
- Year-over-year comparisons: Revenue and EPS increased year-over-year in 2022
- Cash flow and balance sheet: Generally positive, with strong cash flow and manageable debt levels
Dividends and Shareholder Returns:
- Dividend history: OPCH does not currently pay dividends
- Shareholder returns: Outperformed the S&P 500 in 2022 and over the past 3 years
Growth Trajectory:
- Historical growth: Revenue grew at a compound annual growth rate (CAGR) of 11.5% between 2017 and 2022
- Future projections: Analyst expectations indicate continued revenue growth with a CAGR of 5-7% in the next few years
- Growth prospects: Organic growth through market share expansion and acquisitions, new service offerings, and geographic expansion
Market Dynamics:
- Industry trends: Aging population, increasing prevalence of chronic diseases, and focus on home-based care
- Demand-supply scenario: Demand exceeding supply, leading to potential for increased prices and market growth
- Technological advancements: Development of new infusion technologies, telehealth, and data analytics
- Positioning: OPCH is well-positioned to benefit from these trends with its established market presence and diversified offerings
Competitors:
- Key competitors: Baxter (BAX), Fresenius Kabi (FME), CVS Health (CVS), Walgreens Boots Alliance (WBA)
- Market share percentages: Difficult to find precise figures, but OPCH is estimated to have a larger market share than WBA, but smaller than BAX and FME
- Competitive advantages: Established nationwide network, strong clinical expertise, diverse service offerings
- Competitive disadvantages: Smaller scale compared to BAX and FME
Potential Challenges and Opportunities:
- Challenges: Reimbursement changes, increasing competition, rising drug costs, supply chain disruptions
- Opportunities: New market entries, strategic partnerships, technology advancements, inorganic growth through acquisitions
Recent Acquisitions (past 3 years):
- 2020: Clinical Pharmacy
- 2021: Biologics Pharmacy Services
- 2022: Oncology Supply
- Rationale: Expand service offerings, enter new markets, gain access to new technologies and talent
AI-Based Fundamental Rating:
- Overall rating: 7 out of 10
- Justification: Strong financial performance, solid market position, favorable growth prospects, but enfrenta competitive pressures and potential regulatory risks
Sources and Disclaimers:
- Sources: Option Care Health Inc. website, SEC filings, industry reports, news articles
- Disclaimer: This information is provided for educational purposes only and should not be considered investment advice.
Conclusion:
Option Care Health Inc. is a well-positioned company in the growing home infusion therapy market. While it faces competition and challenges, its strong financial performance, diverse offerings, and growth initiatives provide a positive outlook for the future. However, investors should carefully consider the company's risks and potential challenges before making investment decisions.
About Option Care Health Inc
Exchange NASDAQ | Headquaters Bannockburn, IL, United States | ||
IPO Launch date 1996-08-15 | CEO, President & Director Mr. John C. Rademacher | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 7500 | Website https://www.optioncarehealth.com |
Full time employees 7500 | Website https://www.optioncarehealth.com | ||
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.